Area of research
Pulmonary and Respiratory Medicine · Molecular Biology
Research interest
Research interests include Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies, and Melanoma and MAPK Pathways.
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2–Activating Mutations: Results From the National Cancer Institute–Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B
Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF<sup>V600E</sup></i> Mutations: Results of the NCI-MATCH Trial Subprotocol H
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
Effect of Capivasertib in Patients With an <i>AKT1 E17K</i>-Mutated Tumor
Nivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) Study
Abstract CT138: NCI-MATCH EAY131 -Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing <i>BRCA1</i> and <i>BRCA2</i> mutations
Abstract CT138: NCI-MATCH EAY131 -Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing<i>BRCA1</i>and<i>BRCA2</i>mutations
Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway.
Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial.
Current State of PCR-Based Epstein-Barr Virus DNA Testing for Nasopharyngeal Cancer
Clinical Utility of Epstein-Barr Virus DNA Testing in the Treatment of Nasopharyngeal Carcinoma Patients
Criteria for the use of omics-based predictors in clinical trials
Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration
Development and Use of Integral Assays in Clinical Trials